Not Yet Recruiting
A Phase 1b/2 Study of Ropeginterferon Alfa-2b Added to Azacitidine in Newly Diagnosed MDS/AML (≥ 10% Blasts) With TP53 Mutations
NCT07646821
- Conditions
- Alfa-2b, Azacitidine, MDS/AML, +1 more
- Locations
-
- MD Anderson Cancer Center Houston, Texas, United States